Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)

NCT02630368 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT02630368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02630368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)
Lead sponsor
Institut Bergonié
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 18, 2015
Completion date
November 30, 2024
Enrollment
197 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, soft-tissue sarcoma, solid tumors